Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Clinical colorectal cancer - 18(2019), 4 vom: 30. Dez., Seite 307-309 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gong, Jun [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.07.2020 Date Revised 23.07.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clcc.2019.08.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301711275 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301711275 | ||
| 003 | DE-627 | ||
| 005 | 20231225105208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clcc.2019.08.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1005.xml |
| 035 | |a (DE-627)NLM301711275 | ||
| 035 | |a (NLM)31563511 | ||
| 035 | |a (PII)S1533-0028(19)30282-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gong, Jun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.07.2020 | ||
| 500 | |a Date Revised 23.07.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Checkpoint inhibitor | |
| 650 | 4 | |a Metastatic colorectal cancer | |
| 650 | 4 | |a Microsatellite stable | |
| 650 | 4 | |a Mismatch repair proficient | |
| 650 | 4 | |a Tumor mutational burden | |
| 650 | 7 | |a ARID1A protein, human |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a DNA-Binding Proteins |2 NLM | |
| 650 | 7 | |a G-T mismatch-binding protein |2 NLM | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 650 | 7 | |a TGFB1 protein, human |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a Transforming Growth Factor beta1 |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 700 | 1 | |a Robertson, Mandy D |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Fakih, Marwan |e verfasserin |4 aut | |
| 700 | 1 | |a Schrock, Alexa B |e verfasserin |4 aut | |
| 700 | 1 | |a Tam, Kit W |e verfasserin |4 aut | |
| 700 | 1 | |a Burugapalli, Bhuvaneswari |e verfasserin |4 aut | |
| 700 | 1 | |a Monjazeb, Arta M |e verfasserin |4 aut | |
| 700 | 1 | |a Hendifar, Andrew E |e verfasserin |4 aut | |
| 700 | 1 | |a Hitchins, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Klempner, Samuel J |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, May |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical colorectal cancer |d 2000 |g 18(2019), 4 vom: 30. Dez., Seite 307-309 |w (DE-627)NLM122314204 |x 1938-0674 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g number:4 |g day:30 |g month:12 |g pages:307-309 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clcc.2019.08.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2019 |e 4 |b 30 |c 12 |h 307-309 | ||